Skip to content
Peptigraph home

VENTURE: VK2735 Phase 2 trial (NCT06068946)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
176
actual
Start
31 Aug 2023 (actual)
Primary completion
27 Feb 2024 (actual)
Sponsor
Viking Therapeutics, Inc.
Design

Arms and doses

NCT06068946 study arms
ArmTypeInterventionsDescription
VK2735 (Placebo)Placebo comparatorBiological: PlaceboPlacebo
VK2735 (Dose #1)ExperimentalBiological: VK2735VK2735 is a peptide GLP-1 and GIP dual agonist
VK2735 (Dose #2)ExperimentalBiological: VK2735VK2735 is a peptide GLP-1 and GIP dual agonist
VK2735 (Dose #3)ExperimentalBiological: VK2735VK2735 is a peptide GLP-1 and GIP dual agonist
VK2735 (Dose #4)ExperimentalBiological: VK2735VK2735 is a peptide GLP-1 and GIP dual agonist
Endpoints

Primary endpoint

NCT06068946 primary outcomes
MeasureTime frame
Percent (relative) change from baseline to Week 13 in body weight13 weeks
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT06068946 secondary outcomes
MeasureTime frame
Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 1313 weeks
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid ConditionClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.